Geron Corporation (GERN) - Total Liabilities
Based on the latest financial reports, Geron Corporation (GERN) has total liabilities worth $318.68 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Geron Corporation to assess how effectively this company generates cash.
Geron Corporation - Total Liabilities Trend (1996–2024)
This chart illustrates how Geron Corporation's total liabilities have evolved over time, based on quarterly financial data. Check GERN financial resilience to evaluate the company's liquid asset resilience ratio.
Geron Corporation Competitors by Total Liabilities
The table below lists competitors of Geron Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daoming Optics&Chemical Co Ltd
SHE:002632
|
China | CN¥872.63 Million |
|
UP FINT. HLDG (SP.ADR) A
F:1M5
|
Germany | €8.48 Billion |
|
Tian Jin Motor Dies Co Ltd
SHE:002510
|
China | CN¥3.87 Billion |
|
Beijing UniStrong Science & Technology Co Ltd
SHE:002383
|
China | CN¥1.28 Billion |
|
Changsha DIALINE New Material Sci & Tech Co Ltd
SHE:300700
|
China | CN¥848.12 Million |
|
Shentong Technology Group Co Ltd
SHG:605228
|
China | CN¥1.32 Billion |
|
Planisware SAS
PA:PLNW
|
France | €104.23 Million |
|
Indocement Tunggal Prakarsa
JK:INTP
|
Indonesia | Rp7.37 Trillion |
Liability Composition Analysis (1996–2024)
This chart breaks down Geron Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GERN market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Geron Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Geron Corporation (1996–2024)
The table below shows the annual total liabilities of Geron Corporation from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $313.46 Million | +114.51% |
| 2023-12-31 | $146.13 Million | +32.15% |
| 2022-12-31 | $110.58 Million | +11.00% |
| 2021-12-31 | $99.62 Million | +66.64% |
| 2020-12-31 | $59.78 Million | +96.89% |
| 2019-12-31 | $30.36 Million | +302.09% |
| 2018-12-31 | $7.55 Million | +15.88% |
| 2017-12-31 | $6.52 Million | -17.19% |
| 2016-12-31 | $7.87 Million | +18.62% |
| 2015-12-31 | $6.63 Million | -84.13% |
| 2014-12-31 | $41.80 Million | +450.93% |
| 2013-12-31 | $7.59 Million | -46.37% |
| 2012-12-31 | $14.15 Million | +5.24% |
| 2011-12-31 | $13.44 Million | -67.09% |
| 2010-12-31 | $40.85 Million | +423.37% |
| 2009-12-31 | $7.80 Million | +0.54% |
| 2008-12-31 | $7.76 Million | -41.29% |
| 2007-12-31 | $13.22 Million | -71.80% |
| 2006-12-31 | $46.88 Million | +344.88% |
| 2005-12-31 | $10.54 Million | +7.42% |
| 2004-12-31 | $9.81 Million | -16.80% |
| 2003-12-31 | $11.79 Million | -61.88% |
| 2002-12-31 | $30.93 Million | -10.84% |
| 2001-12-31 | $34.69 Million | -30.78% |
| 2000-12-31 | $50.11 Million | +33.63% |
| 1999-12-31 | $37.50 Million | +220.51% |
| 1998-12-31 | $11.70 Million | +134.00% |
| 1997-12-31 | $5.00 Million | -3.85% |
| 1996-12-31 | $5.20 Million | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.